Dingdang Health Technology Group Ltd. (HK:9886)
:9886
Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$1.08
-HK$0.02(-3.23%)
At close: 4:00 PM EST
HK$1.08
-HK$0.02(-3.23%)
Day’s Range― - ―
52-Week RangeHK$0.39 - HK$1.37
Previous CloseN/A
Volume431.00K
Average Volume (3M)4.91M
Market Cap
HK$1.20B
Enterprise ValueHK$828.81M
Total Cash (Recent Filing)HK$1.36B
Total Debt (Recent Filing)HK$263.13M
Price to Earnings (P/E)235.1
Beta1.83
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,319,472,900
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$6.85B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA 70% revenue surge signals restored customer demand and stronger adoption of Dingdang's O2O pharmacy model. Sustained top-line growth improves unit economics, supports scale benefits across its pharmacy network, and creates room to invest in operations and customer acquisition over the medium term.
Gross Margin ExpansionHigher gross margins reflect better pricing, improved product mix, or tighter cost control in procurement and fulfillment. A structurally higher gross margin enhances the firm's ability to sustain operating costs, accelerate path to profitability, and better withstand competitive pricing pressure over multiple quarters.
Positive Operating & Free Cash FlowThe swing to positive operating and free cash flow demonstrates improving core cash generation, reducing reliance on external funding. If durable, this strengthens financial flexibility to fund network expansion, technology or working-capital needs, lowering execution risk over the next several quarters.
Bears Say
Persistent Slight Net LossesDespite revenue and margin recovery, the business remained marginally unprofitable in 2025. Ongoing losses constrain retained capital, limit resilience against downturns, and mean the company must sustain operational improvements to convert recent gains into consistent, long-term profitability.
Prior Balance-sheet StressA history of negative equity and high leverage signals past solvency and execution weaknesses. Even with improved leverage recently, this legacy raises scrutiny from creditors and investors and implies the company must consistently prove balance-sheet resilience to avoid renewed funding pressure.
Cash-flow Volatility RiskThe 2025 cash-flow turnaround follows several years of negative cash generation, suggesting volatility. If the improvement is driven by working-capital timing or one-off items rather than recurring operational gains, cash generation may not be durable, constraining capital allocation and growth plans.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.39 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$1.20B.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 89 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,319,472,900 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-11.92%
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. operates as a service provider in the digital retail pharmacy industry in the People's Republic of China. The company offers pharmaceutical retail and medical consultation services. Dingdang Health Technology Group Ltd. was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―
Options Prices
Currently, No data available
---